New drug cocktail tested to shrink tumors before esophageal cancer surgery
NCT ID NCT07312578
Summary
This study is testing whether adding two immunotherapy drugs (nimotuzumab and camrelizumab) to standard chemotherapy before surgery helps patients with a type of esophageal cancer. The goal is to see if this combination can completely eliminate the cancer in the removed tissue and improve survival. About 48 patients with locally advanced but operable cancer will be randomly assigned to receive either the new combination or standard treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of GI Oncology, Peking University Cancer Hospital,
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.